Literature DB >> 9502113

Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines.

V Lelièvre1, A C Meunier, E Caigneaux, J Falcon, J M Muller.   

Abstract

Human colonic adenocarcinoma cell lines have conserved several features of the native tissue. Among these is the expression of cell surface receptors for hormones and neurotransmitters that may be involved in the regulation of proliferation and differentiation processes in these cancer cells. Here, we confirm that high-affinity binding sites for the Vasoactive Intestinal Polypeptide (VIP) and for the VIP analogue Pituitary Adenylate-Cyclase Activating Polypeptide (PACAP), were expressed in 4 human colonic adenocarcinoma cell lines, HT29, SW403, DLD-1 and Caco-2, that spontaneously displayed variable phenotypic properties in culture. We demonstrated that after long-term treatments, VIP and PACAP significantly reduced cell proliferation in the 4 cell lines and modulated intracellular cAMP and cGMP levels. Furthermore, conspicuous differences were observed from one cell type to another concerning expression of the receptor subsets or the effects of the neuropeptides on cell growth and on cyclic nucleotides production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502113     DOI: 10.1016/s0898-6568(97)00067-3

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  10 in total

1.  Antiproliferative effects of PACAP and VIP in serum-starved glioma cells.

Authors:  Agata Grazia D'Amico; Soraya Scuderi; Salvatore Saccone; Alessandro Castorina; Filippo Drago; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2013-07-31       Impact factor: 3.444

2.  Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.

Authors:  Christine Dufes; Céline Alleaume; Alicia Montoni; Jean-Christophe Olivier; Jean-Marc Muller
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

3.  Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP.

Authors:  Nicole Nemetz; Catalina Abad; Greg Lawson; Hiroko Nobuta; Seririthanar Chhith; Lucy Duong; Gary Tse; Jonathan Braun; James A Waschek
Journal:  Int J Cancer       Date:  2008-04-15       Impact factor: 7.396

4.  Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells.

Authors:  Paulina Sokolowska; Jerzy Z Nowak
Journal:  J Mol Neurosci       Date:  2008-05-20       Impact factor: 3.444

Review 5.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

6.  Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.

Authors:  V Lelievre; G Favrais; C Abad; H Adle-Biassette; Y Lu; P M Germano; G Cheung-Lau; J R Pisegna; P Gressens; G Lawson; J A Waschek
Journal:  Peptides       Date:  2007-05-18       Impact factor: 3.750

7.  Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.

Authors:  K Szepeshazi; A V Schally; K Groot; P Armatis; G Halmos; F Herbert; B Szende; J L Varga; M Zarandi
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

8.  Effect of NSAIDs Supplementation on the PACAP-, SP- and GAL-Immunoreactive Neurons in the Porcine Jejunum.

Authors:  Marta Brzozowska; Barbara Jana; Jarosław Całka
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

9.  PACAP38 and PACAP6-38 exert cytotoxic activity against human retinoblastoma Y79 cells.

Authors:  Jakub Wojcieszak; Jolanta B Zawilska
Journal:  J Mol Neurosci       Date:  2014-02-11       Impact factor: 3.444

Review 10.  Protective Effects of PACAP in Peripheral Organs.

Authors:  Denes Toth; Edina Szabo; Andrea Tamas; Tamas Juhasz; Gabriella Horvath; Eszter Fabian; Balazs Opper; Dora Szabo; Grazia Maugeri; Agata G D'Amico; Velia D'Agata; Viktoria Vicena; Dora Reglodi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-14       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.